Veraxa Biotech AG
VRXA · NASDAQ
$1.01+$0.01 (+1.00%)TodayMarket closed ·
Prev close $1.00
Who owns VRXA
Largest institutional holders, from their latest 13F filings
The 10 largest institutions hold 72.9% of VRXA’s shares.
- Deck (David Lukas)18.0%
- Xlife Sciences AG16.3%
- European Molecular Biology Laboratory16.2%
- Edgar (Schoeni Gilbert)15.9%
- Next 6 largest institutions6.4%
- All other shareholders27.1%
| Holder | Shares | % of shares |
|---|---|---|
| Deck (David Lukas) | 25.50M | 18.03% |
| Xlife Sciences AG | 23.03M | 16.29% |
| European Molecular Biology Laboratory | 22.89M | 16.19% |
| Edgar (Schoeni Gilbert) | 22.54M | 15.94% |
| Voyager Acquisition Sponsor Holdco LLC | 4.19M | 2.96% |
| The Goldman Sachs Group, Inc. | 1.75M | 1.24% |
| Barclays Bank PLC | 1.59M | 1.12% |
| Hosseinion (Warren) | 700.00K | 0.50% |
| Schechter Investments | 689.18K | 0.49% |
| PICTON Investments | 175.00K | 0.12% |
Largest mutual fund holders
| Holder | Shares | % of shares |
|---|---|---|
| Merger Fund | 877.10K | 0.62% |
| PICTON Arbitrage Plus Alternative Fund | 275.50K | 0.19% |
| Fidelity NASDAQ Composite Index Fund | 86.01K | 0.06% |
| Fidelity Nasdaq Composite Index ETF | 33.72K | 0.02% |
| PICTON Arbitrage Alternative Fund | 24.20K | 0.02% |
Insider trades
Form 4 filings by officers, directors and large holders
Over the last 6 months, insiders bought $92.71K (3 trades) of VRXA on the open market, with no sales.
| Insider | Type | Shares | Value |
|---|---|---|---|
| Hosseinion Warren | Buy | 6.02K | $10.06K |
| Baumann Oliver Rolf | Buy | 50.00K | $75.00K |
| Antz Christoph Rudiger | Buy | 5.00K | $7.65K |
Short interest
Settled Sep 30, 2026
- Shares short
- 235.02K
- Days to cover
- 4.57
- % of shares outstanding
- 0.17%
- Average daily volume
- 51.43K
- Change since last report
- +12.1%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.